Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance in leukaemia.

P Baines1, P Cumber, R A Padua

  • 1Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, UK.

Bailliere'S Clinical Haematology
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neglected physical human-robot interaction may explain variable outcomes in gait neurorehabilitation research.

Science robotics·2021
Same author

Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Leukemia·2016
Same author

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.

Blood cancer journal·2015
Same author

"This theatre of monstrous guilt:" Horace Walpole and the drama of incest.

Studies in eighteenth-century culture·2012
Same author

Audit Reports-Thiazide treatment in elderly patients: the metabolic cost.

British medical journal (Clinical research ed.)·2010
Same author

Autopsies in children continue to reveal unanticipated discrepancies between autopsy findings and antemortem clinical diagnoses.

Archives of disease in childhood·2009
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Multidrug resistance in blood cancers involves proteins like P-170 and GST, and altered enzyme levels. Detecting these resistance mechanisms offers new diagnostic and therapeutic strategies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multidrug resistance (MDR) significantly impedes chemotherapy efficacy in hematological malignancies.
  • Cellular proteins, such as P-170 (MDR1 gene product) and GST, play key roles in mediating MDR.
  • Mechanisms include drug efflux pumps, altered enzyme expression (e.g., GST), and downregulation of drug targets like Topoisomerase II (Topo II).

Purpose of the Study:

  • To review the mechanisms of multidrug resistance in hematological neoplasms.
  • To discuss methods for detecting drug resistance and its parameters.
  • To explore the clinical implications and potential therapeutic strategies for overcoming MDR.

Main Methods:

  • Review of existing literature on MDR mechanisms in hematological cancers.

Related Experiment Videos

  • Discussion of in vitro cellular assays for drug toxicity.
  • Overview of molecular, immunological, and functional detection methods for resistance proteins (P-170, Topo II) and enzymes (GST).

    • Main Results:

    • MDR mechanisms, including P-170 and GST, can be active even in de novo (treatment-naive) malignancies.
    • While P-170 and GST are often elevated in relapsed disease, their presence in initial diagnoses is noted.
    • Detection assays are under clinical evaluation, with early data suggesting value despite some contradictions.
    • Resistance can also involve downregulation of drug targets like Topo II.

    Conclusions:

    • Multidrug resistance mechanisms are complex and can be present early in malignancy.
    • Developing assays for MDR detection holds promise for routine diagnostic and prognostic applications.
    • Targeting MDR mechanisms, such as inhibiting the P-170 efflux pump, represents a promising therapeutic avenue.